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Erythrodermic psoriasis (EP) and erythroderma exfolia-
tiva (EE) are acute and potentially life-threatening in-
flammatory reactions. We estimated hazard ratios (HRs) 
of 3-year mortality following hospitalization for EP or 
EE compared with general population controls, patients 
hospitalized for psoriasis vulgaris, and toxic epidermal 
necrolysis (TEN), respectively. We identified 26 and 48 
patients with a first-time hospitalization (1997–2010) 
for EP and EE, respectively (10 matched population-
controls for each patient), 1,998 patients with psoriasis 
vulgaris, and 60 patients with TEN. During follow-up, 
8 (30.8%) patients with EP, 19 (39.6%) patients with 
EE, and 34 (56.7%) patients with TEN died. Compared 
with population-controls, adjusted HRs were 4.40 (95% 
CI 1.66–11.70) for EP and 2.16 (1.21–3.82) for EE. Com-
pared with psoriasis vulgaris, adjusted HRs were 1.83 
(0.90–3.73) for EP, and 1.28 (1.01–1.63) for EE. The risk 
was significantly lower in EP (0.38 (0.16–0.91)) and in 
EE (0.50 (0.36–0.71)), compared with TEN. Mortality in 
EP and EE is high, and close follow-up is advised. Key 
words: erythrodermic psoriasis; erythroderma; erythro-
derma exfoliative; mortality; risk; epidemiology. 
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Erythrodermic psoriasis (EP) and exfoliative dermatitis/
erythroderma exfoliativa (EE) are acute, potentially 
life-threatening inflammatory dermatoses, collectively 
referred to as erythroderma. While they predominantly 
occur in men between the ages of 30 and 60 years (1, 
2), the overall incidence of erythroderma among derma-
tology patients ranges from 0.01% to 0.04%, of which 
25% cases are EP, i.e. related to underlying psoriasis 
(3, 4). In the pre-biologics therapy era, it was estimated 
that 1–2.25% of patients with psoriasis would develop 
EP, but data from recent years are lacking (4, 5). There 
are a number of known causes of EE, including drugs, 
malignancies (including cutaneous T-cell lymphoma), 
pityriasis rubra pilaris, and eczema, yet the aetiology 
remains obscure in a number of cases. 
Clinically, erythroderma is characterized by inflam-
mation involving all or most (> 90%) of the body, with 
or without exfoliation. Aside from the distinctive ery-
thema, symptoms may include fever, chills, malaise, 
lymphadenopathy, nail dystrophy, alopecia, and high 
output congestive heart failure (1, 2, 6–8). Moreover, 
patients may lose significant amounts of water, with 
the barrier defect accounting for up to 10% of daily 
water loss (9). Although patients with erythroderma 
are at increased risk of superinfections and sepsis, in 
particular from Staphylococcus aureus (8), systemic 
immunomodulating agents including prednisolone, 
cyclosporine, methotrexate, acitretin, and certain bio-
logics are considered first-line treatment options (5). 
While significant medical advances have occurred 
over the past 2 decades, erythroderma remains classified 
as a potentially fatal condition. However, remarkably 
little is known about the prognosis and mortality in 
these patients. We present data on the 3-year survival 
of all patients in Denmark (1997–2010) hospitalized 
with EP or EE, respectively.
METHODS
Study approval was obtained from the Danish Data Protection 
Agency (ref. 2007-58-0015, int. ref. GEH-2014-018, I-Suite 
02736), and approval from an ethics committee is not required 
for register studies in Denmark. 
The unique civil registration number assigned to each Danish 
resident at birth or on immigration allows for unambiguous 
linkage among all Danish population-based administrative and 
health registries (10). The universal Danish National Health 
Service provides tax-supported healthcare to all residents, with 
unrestricted access to hospitals. The Danish National Patient 
Register contains information on all patients admitted to Da-
nish hospitals, including one primary and up to 19 secondary 
diagnoses coded by discharging physicians, according to the 
Danish version of the International Classification of Diseases, 
10th revision (ICD-10) (11). The primary diagnosis is the main 
reason for hospitalization, and secondary diagnoses are addi-
tional conditions, including complications. Within 14 days of 
death, all deaths and causes of deaths are accurately recorded in 
the National Causes of Death Registry using ICD-10 codes (12).
From the Danish National Patient Registry we identified all 
patients from 1 January 1997, through 31 December 2010, with 
a first-time (inpatient) hospitalization with EP (primary ICD-
10 codes L40.0A and L40.8B) or EE (primary ICD-10 codes 
L26.9A and L53.8C) as the primary cause of admission. No 
patients younger than 35 years of age were hospitalized with 
the aforementioned diagnoses during the study period. Each 
patient was matched on age, sex, and date of admission, to 10 
controls from the general population. In addition, we identified 
all patients aged ≥ 35 years with a first-time (inpatient) hospi-
talization for psoriasis vulgaris (primary ICD-10 code L40.0), 
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or toxic epidermal necrolysis (TEN) (primary ICD-10 code 
L51.2). We have previously examined the medical records of 
50 randomly selected patients consecutively referred for first-
time hospital-based treatment of psoriasis vulgaris, albeit in 
an outpatient setting. The majority of patients were actively 
treated with topical agents when evaluated and presented with 
a mean Psoriasis Area and Severity Index (PASI) score of 10, 
which was consistent with severe psoriasis (13). Similarly, in 
a recent study examining all (n = 250) patients from 2 Danish 
hospitals diagnosed with erythema multiforme, Stevens-
Johnson syndrome, and TEN, respectively, the TEN diagnosis 
was confirmed with a specificity of 100% (14).
Patients were followed 3 years from the date of first hospi-
talization (study start), or until death, whichever came first. 
Comorbidity up to 5 years before study start was classified 
using the Charlson Comorbidity Index, which summarizes 19 
conditions found to have a prognostic effect. Use of the Charl-
son Comorbidity Index in the Danish National Patient Register 
has an overall positive predictive value of 98% (15) and, based 
on this score, patients were categorized into 3 comorbidity 
levels (0, normal; 1, moderate; and ≥ 2, severe). From Statis-
tics Denmark we used information on tax-reported household 
income. This was used to calculate an age-standardized index 
of socioeconomic status between 0 (lowest group) and 4 (high-
est group) based on the mean gross annual income during a 
5-year period before study start. Collection of data on smoking 
history and alcohol abuse has been described elsewhere (16, 
17). The Strengthening the Reporting of Observational Studies 
in Epidemiology recommendations were used for conduct and 
reporting of this study (18).
Statistical analysis 
We described baseline characteristics with means and standard 
deviations for continuous variables and frequencies and per-
centages for categorical variables. We used Kaplan–Meier plots 
and log-rank tests for non-parametric estimation of the 3-year 
mortality. Event rates were calculated per 10 person-years, and 
Cox proportional hazard models were used to estimate crude 
and adjusted (adjusted for age, sex, socioeconomic status, 
smoking, alcohol abuse, and the Charlson Comorbidity Index 
score) hazard ratios (HRs) with 95% confidence intervals (CI). 
Model assumptions were tested and found to be valid. p-values 
< 0.05 were considered statistically significant. SAS version 9.4 
(SAS Institute Inc., Cary, NC, USA) and STATA 11.2 (Stata-
Corp, College Station, TX, USA) were used for data analysis. 
RESULTS
Between 1 January 1997 and 31 December 2010, we 
identified a total of 26 and 48 patients admitted for 
hospital-based treatment of EP and EE, respectively, 
and 260 and 480 matched controls from the general 
population. Similarly, we found 60 and 1,998 patients 
admitted due to TEN and psoriasis vulgaris, respec-
tively. Across the groups there was a male predomi-
nance, except for TEN, which occurred slightly more 
frequently in women. The baseline characteristics are 
shown in Table I.
There were no erythroderma patients with a pre-
existing diagnosis of drug-induced exanthema, but 6 
patients with EE had previously been diagnosed with 
malignant neoplasms of lymphoid, haematopoietic, or 
related tissues (ICD-10 codes C81–C96). Fig. 1 shows 
the non-parametric Kaplan–Meier survival curves 
(p < 0.0001 for trend), and during the 3-year follow-up, 
30.8% (8/26) of patients with EP and 7.7% (20/260) of 
their age- and sex-matched general population controls 
died. Similarly, 39.6% (19/48) of patients with EE and 
14.2% (68/480) of their controls died, while death oc-
curred in 13.6% (272/1998) of patients with psoriasis 
vulgaris, and 56.7% (34/60) of patients with TEN 
(Table II). Cox regression in patients with EP revealed 
adjusted HRs with 95% CI of 4.40 (1.66–11.70) vs. ge-
neral population controls, 1.83 (0.90–3.73) vs. psoriasis 
vulgaris, and 0.38 (0.16–0.91) vs. TEN. In patients with 
Table I. Baseline characteristics of the study population
 
Erythrodermic psoriasis Erythroderma exfoliativa Controls
Cases 
(n = 26)
General population 
controls 
(n = 260)
Cases 
(n = 48)
General population 
controls 
(n = 480)
Psoriasis 
vulgaris 
(n = 1,998)
Toxic epidermal 
necrolysis 
(n = 60)
Age, years, mean (SD) 60.9 (14.6) 60.9 (14.6) 74.3 (9.7) 74.3 (9.7) 57.5 (13.1) 65.5 (15.6)
Women, n (%) 6 (23.1) 60 (23.1) 16 (33.3) 160 (33.3) 866 (43.3) 33 (55.0)
Men, n (%) 20 (76.9) 200 (76.9) 32 (66.7) 320 (66.7) 1132 (56.7) 27 (45.0)
Ethnic origin, n (%)
  Danish 26 (100) 246 (94.6) 48 (100) 454 (94.6) 1910 (95.6) 60 (100)
  Other 0 (0) 14 (5.4) 0 (0) 26 (5.4) 88 (4.4) 0 (0)
Socioeconomic status, mean (SD)a
  vs. general population controls 1.2 (1.7) 2.1 (1.4) 1.9 (1.4) 2.0 (1.4) N/A N/A
  vs. psoriasis vulgaris 1.5 (1.3) N/A 1.4 (1.4) N/A 2.0 (1.4) N/A
  vs. toxic epidermal necrolysis 1.9 (1.5) N/A 1.7 (1.4) N/A N/A 2.4 (1.3)
Smoking, n (%) 7 (26.9) 29 (11.2) 16 (33.3) 64 (13.3) 451 (22.6) 14 (23.3)
Alcohol abuse, n (%) 4 (15.4) 5 (1.9) 4 (8.3) 5 (1.0) 167 (8.4) 6 (10.0)
Charlson Comorbidity Index
  Normal (0) 16 (61.5) 220 (84.6) 25 (52.1) 404 (84.2) 1,391 (69.6) 28 (46.7)
  Moderate (1) 6 (23.1) 23 (8.9) 10 (20.8) 41 (8.5) 289 (14.5) 7 (11.6)
  Severe (≥ 2) 4 (15.4) 17 (6.5) 13 (27.1) 35 (7.3) 318 (15.9) 25 (41.7)
aSocioeconomic status is calculated as an age-standardized index between 0 (lowest group) and 4 (highest group) based on the mean gross annual income 
during 5-year period before study start. The mean socioeconomic status is relative to the comparison groups, hence 3 different values for EE and EP cases.
SD: standard deviation; N/A: not applicable.
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EE, the adjusted HRs were 2.16 (1.21–3.82) vs. gene-
ral population controls, 1.28 (1.01–1.63) vs. psoriasis 
vulgaris, and 0.50 (0.36–0.71) vs. TEN (Table III). In 
patients with EP and EE, deaths were predominantly 
due to major adverse cardiovascular events and cancer 
(approximately 45% of malignancies were lymphomas). 
DISCUSSION
In this population-based cohort study 30.8% and 39.6% 
of patients with EP and EE, respectively, died within 
the first 3 years following hospital admission, whereas 
13.6% of patients with severe psoriasis vulgaris, and 
56.7% of patients with TEN died, respectively, follo-
wing admission. The high 3-year mortality in patients 
with EE and EP, underscores the need for close follow-
up and management of comorbidities in previously 
hospitalized patients. 
Previous data on mortality in patients with erythro-
derma is scarce and limited to reports dating back more 
than 25 years (4, 6, 7, 19, 20). Boyd & Menter (4) 
reported that, during a mean follow-up of 33.5 months 
(range 6–88), 4% of patients with EP who had been seen 
in their outpatient clinic (1979–1987) died. In 1963, 
Abrahams et al. (7) reported an 18% mortality rate in 
EE, whereas Wilson (20) in 1954 stated that 39% of 
his patients had died from complications owing to EE. 
In 1973, Nicolis & Helwig (6) described a 
mortality rate of 64% in EE, while Thest-
rup–Pedersen (19) in 1988 noted that half 
of Danish patients from a single hospital 
diagnosed in the course of 15 years with EE 
of unknown aetiology had died during the 
observation period. 
However, within the last 2 decades, signifi-
cant advances have been made in emergency 
hospital care, and the advent of newer sys-
temic agents, such as anti-tumour necrosis 
factor-α and anti-interleukin 12/23 agents, 
have significantly broadened the therapeutic 
options for patients, in particular those with 
psoriatic disease including EP. Nonetheless, 
we found high mortality rates that were 
comparable with results from much older 
studies (4, 6, 7, 19, 20). Explanations may include poor 
treatment adherence in these patients or a stronger ef-
fect of risk factors. As indicated by our results, patients 
with EP and EE have a lower socioeconomic status and 
a higher prevalence of comorbidities, smoking, and al-
cohol abuse than their general population and psoriasis 
controls. Therefore, we also used patients admitted for 
hospitalized-based treatment of psoriasis vulgaris or 
TEN as control groups, and results from these analyses 
underline the high-risk population posed by patients 
with erythroderma. Notably, while death from TEN usu-
ally occurs shortly after diagnosis, the 3-year mortality 
of EE in our study was comparable to the short-term 
mortality rate in patients with TEN, as indicated by the 
Kaplan–Meier survival curves (see Fig. 1).
Our study was strengthened by the high accuracy of 
the Danish registries, ensuring complete follow-up and 
prospectively recorded information on, for example, 
comorbidity and tax-reported income ensured that re-
call bias was virtually eliminated. However, while we 
used nationwide data, the absolute number of patients 
was low and was limited to those requiring inpatient 
hospital treatment for EP and EE, and results should 
Table II. Summary of follow-up time, number of deaths, and event 
rates per 10 person-years
Person-
years
Deaths 
n (%)
Rate per 10 
person-years 
95% CI
Erythrodermic psoriasis 66.2   8 (30.8) 1.21 (0.60–2.42)
Controls (general population) 748.9 20 (7.7) 0.27 (0.17–0.41)
Erythroderma exfoliativa 107.9 19 (39.6) 1.76 (1.12–2.76)
Controls (general population) 1,321.8 68 (14.2) 0.51 (0.41–0.65)
Controls (psoriasis vulgaris) 5,548.5 272 (13.6) 0.49 (0.44–0.55)
Controls (TEN) 97.6 34 (56.7) 3.49 (2.49–4.88)
CI: confidence interval; TEN: toxic epidermal necrolysis.
Fig. 1. Kaplan–Meier plot of the 3-year survival in patients with psoriasis vulgaris, 
erythrodermic psoriasis, erythroderma exfoliativa, and toxic epidermal necrolysis, 
respectively.
Table III. Crude and adjusted hazard ratios (HR) of all-
cause mortality in patients with erythrodermic psoriasis, and 
erythroderma exfoliativa
Unadjusted HR
(95% CI) p-value
Adjusted HRa
(95% CI) p-value
Erythrodermic psoriasis
  vs. general pop. 4.54 (2.00–10.31) 0.0003 4.40 (1.66–11.70) 0.0003
  vs. PV 2.45 (1.21–4.94) 0.0126 1.83 (0.90–3.73) 0.0933
  vs. TEN 0.39 (0.18–0.84) 0.0169 0.38 (0.16–0.91) 0.0294
Erythroderma exfoliativa
  vs. general pop. 3.37 (2.03–5.61) < 0.0001 2.16 (1.21–3.82) 0.0087
  vs. PV 1.88 (1.49–2.38) < 0.0001 1.28 (1.01–1.63) 0.0448
  vs. TEN 0.73 (0.55–0.97) 0.0297 0.50 (0.36–0.71) 0.0001
aAdjusted for age, sex, socio-economic status, smoking, alcohol, and the 
Charlson Comorbidity Index score.
CI: confidence interval; HR: hazard ratio; pop.: population; PV: psoriasis 
vulgaris; TEN: toxic epidermal necrolysis.
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be interpreted accordingly. Also, we cannot exclude 
the possibility that residual confounding may have 
affected our estimates. In addition, all of our patients 
were of Danish origin, i.e. Caucasian decent, but 
while erythroderma have been reported previously in 
a limited number of patients with darker skin (4, 6, 7), 
extrapolation of our results to such individuals may be 
limited. Lastly, while the majority of deaths were due 
to cardiovascular disease and malignancies, whether 
these deaths were directly attributable to erythroderma 
remains unknown. 
In conclusion, we found a high 3-year mortality rate 
in patients with EP and EE. These patients pose a high-
risk population with excess of comorbidities and low 
socioeconomic status, and we recommend that they are 
closely followed with focus on modifiable risk factors.
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